**
Individuals in the UK suffering from hypermobility conditions endure staggering waits for diagnosis, with some waiting as long as 21 years, according to a recent study conducted by the University of Edinburgh. The research, which surveyed over 2,000 participants, sheds light on the inadequacies in awareness and understanding of hypermobility spectrum disorders (HSD) and hypermobile Ehlers-Danlos syndrome (hEDS) among healthcare professionals, revealing a pressing need for improved care pathways.
The Burden of Misdiagnosis
Hypermobile Ehlers-Danlos syndrome and related disorders affect connective tissues throughout the body, leading to symptoms such as chronic pain, frequent joint dislocations, and fatigue, along with various neurological, gastrointestinal, and psychological issues. Unfortunately, many patients are left in limbo for years, battling debilitating symptoms while navigating a fragmented healthcare system.
Prominent writer and actress Lena Dunham recently shared her personal struggle with hEDS in her book, *Famesick*. Dunham recounted how she dismissed her symptoms—including migraines and fainting spells—as mere quirks until a diagnosis in her late twenties. Her experience reflects a broader trend, where the diffuse nature of such symptoms often leads to them being overlooked or misattributed.
Fragmented Healthcare and Its Consequences
The study highlighted that nearly 46% of respondents were unemployed, with 48% relying on disability-related benefits. A significant 84% of participants reported chronic pain, while 74% experienced partial dislocations. Additionally, 71% faced anxiety and 63% depression, indicating that the prolonged diagnostic journey significantly impacts not just physical health but mental well-being and social functioning.
Kathryn Berg, trial and data manager at the University of Edinburgh’s Institute of Genetics and Cancer, emphasised the urgent need for comprehensive, multidisciplinary care. “Our findings show the profound impact hEDS and HSD can have across every aspect of life,” she noted, calling for equitable care pathways that acknowledge the complex nature of these conditions.
Long Diagnostic Journeys Across the UK
The research revealed striking regional disparities in diagnosis times. Participants from Wales reported the longest waits, averaging 21.7 years, followed closely by Northern Ireland at 21.1 years, Scotland at 19.5 years, and England at 19 years. Alarmingly, more than a third of respondents from Wales and Northern Ireland had to seek diagnoses outside their home regions, with 17% of those in Scotland doing the same. In contrast, England had a notably higher diagnosis rate within its borders at 98%.
These delays in diagnosis are not merely a logistical issue but a significant barrier to accessing appropriate care. A Welsh government representative acknowledged the challenges faced by patients, noting efforts to create consistent health pathways aimed at improving access to specialist care.
Government Initiatives and Support
In response to the alarming findings, UK government officials have expressed their commitment to improving the recognition and management of hypermobility disorders. A toolkit, developed by the Royal College of General Practitioners in collaboration with EDS Support UK, has been rolled out to aid clinicians in identifying and managing these complex conditions. The aim is to foster greater awareness and provide a more coherent approach to care.
Why it Matters
The long wait times for diagnosis of hypermobility disorders underscore a broader systemic issue within the UK healthcare framework. Not only do these delays inflict unnecessary suffering on patients, but they also hinder their ability to lead fulfilling lives. As awareness grows and initiatives are implemented, there is hope for a future where individuals with hEDS and HSD receive timely, effective care, thereby improving their overall quality of life. The findings of this study should act as a catalyst for change, urging both healthcare providers and policymakers to prioritise the needs of this underserved patient population.
